Nathalie Le Bastard

Gent, VLG 9052, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers.

Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers.

Journal: EBioMedicine

Published: November 04, 2025

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic.

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: October 23, 2024

Correction: Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy.

Correction: Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy.

Journal: Molecular neurodegeneration

Published: October 14, 2024

Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells.

Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: July 10, 2024

Association of Structural Forms of 17q21.31 with the Risk of Progressive Supranuclear Palsy and MAPT Sub-haplotypes.

Association of Structural Forms of 17q21.31 with the Risk of Progressive Supranuclear Palsy and MAPT Sub-haplotypes.

Journal: medRxiv : the preprint server for health sciences

Published: March 11, 2024

Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy.

Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy.

Journal: Molecular neurodegeneration

Published: January 29, 2024

Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.

Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.

Journal: Alzheimer's research & therapy

Published: July 25, 2023

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: September 02, 2022

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.

Journal: Clinical chemistry and laboratory medicine

Published: January 01, 2021

Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.

Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: December 11, 2020

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: August 22, 2019

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Journal: Annals of clinical and translational neurology

Published: May 10, 2019

Showing 1-12 of 28

Last Updated: 09/26/2026